Additionally, the team observed that blocking programmed death-ligand 1 (PD-L1) enhanced the effects of such a combination, further validating the WEE1i-ATRi-PD-L1 antibody triple combination effectiveness for cancer treatment. This evidence concerns the gene CD274 and cancer.